Not Yet RecruitingPhase 2

Dara-BCD for Rare MGRS

10 participantsStarted 2025-01-15

Plain-language summary

This is an open-label, multicenter, phase 2 study in subjects with newly diagnosed proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMIDs), OR light chain proximal tubulopathy (LCPT), OR thrombotic Microangiopathy (TMA), OR cryoglobulinemic glomerulonephritis, (CGGN), treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of PGNMIDs, OR LCPT, OR TMA, OR CGGN.
✓. Evidence of clonal plasma cell in bone marrow.
✓. ECOG 0,1,2
✓. Neu≥ 1.0\*10\^9/L, HGB ≥70g/L, PLT ≥ 50\*10\^9/L.
✓. Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN;
✓. Informed consent explained to, understood by and signed by the patient.

Exclusion criteria

✕. Prior therapy for MGRS, with the exception of equal or less than 160 mg dexamethasone (or equivalent corticosteroid)
✕. Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.
✕. Presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis;
✕. Severe or persistent infection that cannot be effectively controlled;
✕. Presence of severe autoimmune diseases or immunodeficiency disease;
✕. Patients with active hepatitis B or hepatitis C (\[HBVDNA+\] or \[HCVRNA+\]); Patients with HIV infection or syphilis infection;
✕. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.

What they're measuring

Rate of Hematologic Complete Response at the completion of 6 cycles

Timeframe: 6 months

Trial details

NCT IDNCT06771180

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-31

Contact for this trial

Yang Liu

86-13716926210 pkuphliuyang@bjmu.edu.cn

View on ClinicalTrials.gov More Monoclonal Gammopathy of Renal Significance (MGRS) trials